Revive Therapeutics (TSXV:RVV, OTCQB:RVVTF) announced a sponsored research agreement with the University of Wisconsin-Madison in order to check a drug delivery technology using cannabinoids for various diseases.
As quoted in the press release:
“We are very excited to advance a novel cannabinoid-focused drug delivery technology with the potential to safely and effectively treat, but not limited to, pain, inflammatory skin disorders, and liver diseases,” said Craig Leon, Chief Executive of Revive. “We are focused on continuing to build our cannabinoid-based product pipeline and our expansion in cannabinoid-based drug delivery reinforces our commitment to this strategy. Our research relationship with the University of Wisconsin-Madison builds upon our efforts to lead the way in providing novel cannabinoid-based therapies for serious and unmet medical needs.”
The research program will be led by Jess D. Reed, Ph.D., Professor of Animal Sciences at the University of Wisconsin-Madison. Under the agreement, Dr. Reed and his research team will evaluate the role and potential use of a chitosan-tannins based formula for the delivery of cannabinoids. The research will be based on Dr. Reed’s patented technology in the use of tannin-chitosan composites for therapeutic biomaterials.
“I am very excited about the potential and the initiation of the development of a novel ground-breaking cannabinoid-focused drug delivery technology,” said Dr. Jess Reed, Professor of Animal Sciences at the University of Wisconsin-Madison. “The opportunities of the drug delivery technology and cannabinoids are plentiful and I look forward to validating the true potential of the drug delivery technology in allowing novel ways to deliver cannabinoids for various diseases.”